US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nexentis Technologies Inc

1.08

-0.3100-22.30%

Post-market: 1.05-0.0300-2.78%17:52 EDT

Volume:18.38M

Turnover:29.30M

Market Cap:1.57M

PE:-0.03

High:1.19

Open:1.12

Low:0.9400

Close:1.39

52wk High:49.00

52wk Low:0.9400

Shares:1.45M

Float Shares:1.15M

Volume Ratio:3,037.88

T/O Rate:1598.69%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-33.5835

EPS(LYR):-34.9551

ROE:-454.82%

ROA:-29.54%

PB:0.82

PE(LYR):-0.03

Loading ...

Overview Company News Filings

Nexentis Technologies - Mitocarex to Retain Full Control Over Discovery Programs and Candidates

THOMSON REUTERS

Nexentis Technologies - Announces Mitocarex Engagement With Boltz for AI-Driven Slc Small-Molecule Discovery

THOMSON REUTERS

Nexentis unit MitoCareX partners with Boltz on AI-driven SLC small-molecule discovery

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Nexentis Technologies - Subsidiary Mitocarex Completes Broad Analysis of Human Slc Transport Proteins

THOMSON REUTERS

Nexentis Technologies - Mitocarex Identifies Additional Slc Proteins Compatible With Mitoline Ruleset

THOMSON REUTERS

Nexentis unit MitoCareX completes broad structural analysis of human SLC transport proteins

Nexentis Technologies Inc trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:38 PM

Nexentis announces private placement of 311,876 warrants exercisable at $4.01 per share

Nexentis amends L.I.A. Pure Capital facility, raising credit line to EUR 10 million

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:49 PM

Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone

Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program

Nexentis Announces Mitocarex Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

THOMSON REUTERS

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Nexentis Q1 FY26 net loss widens to $6.59 million

Nexentis unit MitoCareX Bio generates optimized hit molecule in MITOLINE drug program

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

Nexentis Technologies Inc trading resumes

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/NXTS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NXTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXTS\",,,,,undefined,":{"symbol":"NXTS","market":"US","secType":"STK","nameCN":"Nexentis Technologies Inc","latestPrice":1.08,"timestamp":1791403200000,"preClose":1.39,"halted":0,"volume":18378549,"hourTrading":{"tag":"盘后","latestPrice":1.05,"preClose":1.08,"latestTime":"17:52 EDT","volume":41900,"amount":43866.367,"timestamp":1791409969666,"change":-0.03,"changeRate":-0.027778,"amplitude":0.074074},"delay":0,"changeRate":-0.22302158273381284,"floatShares":1149600,"shares":1453300,"eps":-33.583527,"marketStatus":"Post-Mkt","change":-0.31,"latestTime":"10-07 17:52:51 EDT","open":1.12,"high":1.185,"low":0.94,"amount":29303916.374187,"amplitude":0.176259,"askPrice":1.1,"askSize":135,"bidPrice":1.02,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-33.583527,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.39,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.39,"latestTime":"09:29 EDT","volume":8207497,"amount":13887496.9403494,"timestamp":1791379799999,"change":-0.26,"changeRate":-0.18705,"amplitude":0.776978},"postHourTrading":{"tag":"盘后","latestPrice":1.05,"preClose":1.08,"latestTime":"17:52 EDT","volume":41900,"amount":43866.367,"timestamp":1791409969666,"change":-0.03,"changeRate":-0.027778,"amplitude":0.074074},"volumeRatio":3037.87706},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXTS\",,,,,undefined,":{"symbol":"NXTS","floatShares":1149600,"roa":"-29.54%","roe":"-454.82%","lyrEps":-34.955117,"volumeRatio":3037.87706,"shares":1453300,"dividePrice":0,"high":1.185,"amplitude":0.176259,"preClose":1.39,"low":0.94,"week52Low":0.94,"pbRate":"0.82","psRate":"7.51","week52High":49,"institutionHeld":0,"latestPrice":1.08,"committee":-0.970803,"eps":-33.583527,"divideRate":0,"volume":18378549,"delay":0,"ttmEps":-33.583527,"open":1.12,"prevYearClose":11.76,"prevWeekClose":1.49,"prevMonthClose":1.39,"prevQuarterClose":1.39,"fiveDayClose":1.39,"twentyDayClose":1.69,"sixtyDayClose":2.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NXTS","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-25.96},{"market":"US","date":"2026-05-14","symbol":"NXTS","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-12.1},{"market":"US","date":"2026-04-08","symbol":"NXTS","defaultRemindTime":1775655000000,"type":"split","dateTimestamp":1775620800000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2026-03-31","symbol":"NXTS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774987200000,"name":null,"time":"Post-Mkt","dateTimestamp":1774929600000,"actualEps":null},{"market":"US","date":"2025-11-13","symbol":"NXTS","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-8.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NXTS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NXTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NXTS","date":"2026-10-06","current":-0.032159,"percent":0.927152,"low":-1.066842,"twenty":-0.451599,"median":-0.327659,"eighty":-0.147321,"high":-0.087052,"avg":-0.366951,"sd":0.251295,"marketCap":2005599},"quantilePoints":[{"date":"2026-02-27","current":-0.435167,"twenty":-0.435167,"median":-0.435167,"eighty":-0.435167,"marketCap":2892119},{"date":"2026-03-06","current":-0.397016,"twenty":-0.415225,"median":-0.395474,"eighty":-0.392918,"marketCap":2638567},{"date":"2026-03-13","current":-0.363639,"twenty":-0.415225,"median":-0.392918,"eighty":-0.384468,"marketCap":2416744},{"date":"2026-03-20","current":-0.308842,"twenty":-0.397016,"median":-0.38658,"eighty":-0.344965,"marketCap":2052562},{"date":"2026-03-27","current":-0.285858,"twenty":-0.393932,"median":-0.363723,"eighty":-0.300138,"marketCap":1899813},{"date":"2026-04-02","current":-0.277831,"twenty":-0.393121,"median":-0.344965,"eighty":-0.278879,"marketCap":1846463},{"date":"2026-04-10","current":-0.848002,"twenty":-0.4161,"median":-0.367697,"eighty":-0.282571,"marketCap":3395402},{"date":"2026-04-17","current":-0.723994,"twenty":-0.439299,"median":-0.384468,"eighty":-0.285385,"marketCap":2898870},{"date":"2026-04-24","current":-0.913654,"twenty":-0.754631,"median":-0.392896,"eighty":-0.297282,"marketCap":3658271},{"date":"2026-05-01","current":-0.869886,"twenty":-0.840693,"median":-0.397016,"eighty":-0.307101,"marketCap":3483025},{"date":"2026-05-08","current":-1.066842,"twenty":-0.847273,"median":-0.423688,"eighty":-0.318981,"marketCap":4271634},{"date":"2026-05-15","current":-0.846179,"twenty":-0.852197,"median":-0.435167,"eighty":-0.327296,"marketCap":3388100},{"date":"2026-05-22","current":-0.343676,"twenty":-0.848732,"median":-0.423688,"eighty":-0.328308,"marketCap":3227457},{"date":"2026-05-29","current":-0.389551,"twenty":-0.847455,"median":-0.408608,"eighty":-0.337702,"marketCap":3658271},{"date":"2026-06-05","current":-0.393439,"twenty":-0.846544,"median":-0.402769,"eighty":-0.343909,"marketCap":3694781},{"date":"2026-06-12","current":-0.389551,"twenty":-0.845085,"median":-0.400825,"eighty":-0.344605,"marketCap":3658271},{"date":"2026-06-18","current":-0.41521,"twenty":-0.843625,"median":-0.40238,"eighty":-0.345693,"marketCap":3899235},{"date":"2026-06-26","current":-0.404324,"twenty":-0.843625,"median":-0.404324,"eighty":-0.347408,"marketCap":3797008},{"date":"2026-07-02","current":-0.346912,"twenty":-0.841798,"median":-0.401991,"eighty":-0.346811,"marketCap":3257847},{"date":"2026-07-10","current":-0.296353,"twenty":-0.837411,"median":-0.396005,"eighty":-0.33693,"marketCap":2783048},{"date":"2026-07-17","current":-0.192902,"twenty":-0.831221,"median":-0.393439,"eighty":-0.322528,"marketCap":1811538},{"date":"2026-07-24","current":-0.148565,"twenty":-0.81881,"median":-0.391991,"eighty":-0.29711,"marketCap":1395176},{"date":"2026-07-31","current":-0.120563,"twenty":-0.775056,"median":-0.389551,"eighty":-0.285858,"marketCap":1132211},{"date":"2026-08-07","current":-0.149732,"twenty":-0.773232,"median":-0.388693,"eighty":-0.278845,"marketCap":1406133},{"date":"2026-08-14","current":-0.151677,"twenty":-0.767761,"median":-0.384288,"eighty":-0.263889,"marketCap":1424395},{"date":"2026-08-21","current":-0.163224,"twenty":-0.751348,"median":-0.380998,"eighty":-0.192902,"marketCap":2615999},{"date":"2026-08-28","current":-0.173199,"twenty":-0.729465,"median":-0.372447,"eighty":-0.170479,"marketCap":2775866},{"date":"2026-09-04","current":-0.152343,"twenty":-0.723994,"median":-0.363639,"eighty":-0.163224,"marketCap":2441599},{"date":"2026-09-11","current":-0.15325,"twenty":-0.513667,"median":-0.348341,"eighty":-0.16091,"marketCap":2456132},{"date":"2026-09-18","current":-0.124232,"twenty":-0.456877,"median":-0.345876,"eighty":-0.156891,"marketCap":1991066},{"date":"2026-09-25","current":-0.132393,"twenty":-0.453191,"median":-0.343676,"eighty":-0.153069,"marketCap":2121866},{"date":"2026-10-02","current":-0.129673,"twenty":-0.45191,"median":-0.331603,"eighty":-0.149499,"marketCap":2078266},{"date":"2026-10-06","current":-0.125139,"twenty":-0.451599,"median":-0.327659,"eighty":-0.147321,"marketCap":2005599}],"updateTime":1791409334459},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXTS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645402237","title":"Nexentis Technologies - Mitocarex to Retain Full Control Over Discovery Programs and Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2645402237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645402237?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:23","pubTimestamp":1782131005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U0JS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022377","title":"Nexentis Technologies - Announces Mitocarex Engagement With Boltz for AI-Driven Slc Small-Molecule Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022377?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:23","pubTimestamp":1782131005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022326","title":"Nexentis unit MitoCareX partners with Boltz on AI-driven SLC small-molecule discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022326","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022326?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:22","pubTimestamp":1782130961,"startTime":"0","endTime":"0","summary":"Nexentis subsidiary MitoCareX entered an engagement with Boltz to speed AI-led discovery of small molecules targeting selected SLC transporters.Collaboration combines MitoCareX’s MITOLINE-enabled 3D structural modeling with Boltz foundation models for structure prediction, binding affinity, screening, molecule design.Initial work targets a defined set of SLC proteins; scope may expand if early virtual screening results support additional discovery programs.MitoCareX retains control of its programs and any candidates advanced using the combined platform.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL8HlJSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4093","BK4112","NDAQ","NXTS","BK4585","SG9999014013.SGD","BK4588","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645225890","title":"Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2645225890","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645225890?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:22","pubTimestamp":1782130920,"startTime":"0","endTime":"0","summary":"MITOLINE-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June  22,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315270/0/en/Nexentis-Technologies-Announces-International-AI-Drug-Discovery-Initiative-Between-MitoCareX-Bio-and-Boltz-to-Accelerate-Novel-SLC-Small-Molecule-Discovery.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","AIPO","CHAT","ARTY","BK4093","AGIX","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743158","title":"Nexentis Technologies - Subsidiary Mitocarex Completes Broad Analysis of Human Slc Transport Proteins","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644743158?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:32","pubTimestamp":1781695967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P08N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644274311","title":"Nexentis Technologies - Mitocarex Identifies Additional Slc Proteins Compatible With Mitoline Ruleset","url":"https://stock-news.laohu8.com/highlight/detail?id=2644274311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644274311?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:32","pubTimestamp":1781695967,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P08N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644074316","title":"Nexentis unit MitoCareX completes broad structural analysis of human SLC transport proteins","url":"https://stock-news.laohu8.com/highlight/detail?id=2644074316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644074316?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:32","pubTimestamp":1781695945,"startTime":"0","endTime":"0","summary":"Nexentis subsidiary MitoCareX completed a broad structural analysis of human SLC transport proteins to expand its small-molecule discovery engine.Work extends MITOLINE, previously used for mitochondrial SLC25 carriers, to identify non-SLC25 targets compatible with its modeling ruleset.MitoCareX plans to use MITOLINE-derived 3D models in virtual screening for selected non-mitochondrial SLC targets.Move could widen MitoCareX’s addressable transporter set for hard-to-treat cancers and inflammatory metabolic diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6JzrNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","BK4588","IE00BN0W2T93.GBP","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4093","SG9999014039.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","NXTS","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767840","title":"Nexentis Technologies Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767840","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767840?lang=en_us&edition=fundamental","pubTime":"2026-06-17 03:40","pubTimestamp":1781638809,"startTime":"0","endTime":"0","summary":"15:38 EDT Nexentis Technologies (NXTS) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-inc-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-inc-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644003762","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:38 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2644003762","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644003762?lang=en_us&edition=fundamental","pubTime":"2026-06-17 03:38","pubTimestamp":1781638685,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:38 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nAQN2M3S4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643183262","title":"Nexentis announces private placement of 311,876 warrants exercisable at $4.01 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2643183262","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643183262?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:17","pubTimestamp":1781295431,"startTime":"0","endTime":"0","summary":"Nexentis Technologies entered a securities purchase agreement for a registered direct offering of 311,876 common shares.Concurrent private placement to the same investors covers 311,876 unregistered warrants, exercisable at USD 4.01 per share for five years.Gross proceeds from the combined offerings expected at about USD 1.25 million; closing targeted for about June 15, 2026.Resale registration statement for warrant shares due within 30 days of closing; effectiveness targeted within 60 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL4ng98h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638357256","title":"Nexentis amends L.I.A. Pure Capital facility, raising credit line to EUR 10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638357256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638357256?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:16","pubTimestamp":1779912990,"startTime":"0","endTime":"0","summary":"Nexentis Technologies amended and restated its facility agreement with L.I.A. Pure Capital, lifting the credit facility to EUR 10 million from EUR 6 million.The revised terms keep the lender’s five-year warrant for 1,850,000 common shares at an exercise price of $1.The warrant adds a “price maintenance” anti-dilution feature that can cut the exercise price or raise warrant shares on below-strike issuances.Other core facility economics, including interest rate, repayment structure, drawdown period, and general warrant terms, remain largely unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLLPPsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636005584","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:49 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636005584","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636005584?lang=en_us&edition=fundamental","pubTime":"2026-05-19 02:49","pubTimestamp":1779130168,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:49 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nAQN2LZHIL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636426079","title":"Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2636426079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636426079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:36","pubTimestamp":1779111360,"startTime":"0","endTime":"0","summary":"Nexentis Technologies (NXTS) announced that its wholly owned subsidiary, MitoCareX Bio achieved its first drug discovery milestone since its acquis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-says-mitocarex-bio-achieves-drug-discovery-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-says-mitocarex-bio-achieves-drug-discovery-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636578079","title":"Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program","url":"https://stock-news.laohu8.com/highlight/detail?id=2636578079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636578079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:30","pubTimestamp":1779111034,"startTime":"0","endTime":"0","summary":"MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, generated an optimized hit molecule with improved pharmaceutical properties versus the program’s initial hit compound, based on parameters assessed as of March 31, 2026.The milestone advances MitoCareX’s small-molecule program targeting a mitochondrial SLC25 carrier protein, aimed at potential treatments for hard-to-treat cancers and inflammatory metabolic diseases.MitoCareX is moving toward pre-clinical trials while continuing medicinal chemistry work to progress to a lead molecule.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9W6zTh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","NXTS","LU0314104364.USD","BK4585","LU2095319765.USD","BK4093","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","BK4112","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636669079","title":"Nexentis Announces Mitocarex Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2636669079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636669079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:30","pubTimestamp":1779111000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4CMCWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071850","title":"Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071850","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636071850?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:30","pubTimestamp":1779111000,"startTime":"0","endTime":"0","summary":"Ness Ziona, Israel, May  18, 2026  (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (\"Nexentis\" or the \"Company\"), a drug discovery company that also invests in solar energy assets based ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296731/0/en/Nexentis-Announces-MitoCareX-Bio-Achieves-Key-R-D-Milestone-Generating-a-Substantially-Improved-Hit-Molecule-on-the-Path-to-Pre-Clinical-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725106","title":"Nexentis Q1 FY26 net loss widens to $6.59 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725106","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725106?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:23","pubTimestamp":1778790234,"startTime":"0","endTime":"0","summary":"Nexentis Technologies posted a net loss of USD 6.59 million for the three months ended March 31, 2026, widening from USD 1.26 million a year earlier.Net loss from continued operations widened to USD 7.45 million from USD 1.12 million, driven by a non-cash goodwill impairment charge of USD 6.3 million tied to the MitoCareX reporting unit.General and administrative expense climbed 278% to USD 1.9 million, while research and development expense rose to USD 275,000 from no research and development expense.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Secur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbyly9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700786","title":"Nexentis unit MitoCareX Bio generates optimized hit molecule in MITOLINE drug program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635700786?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:13","pubTimestamp":1778670802,"startTime":"0","endTime":"0","summary":"Nexentis said wholly owned unit MitoCareX generated an optimized hit molecule with improved pharmaceutical properties versus its initial hit compound, marking its first drug-discovery milestone since Nexentis acquired the business.Work targets a mitochondrial SLC25 carrier protein, with development aimed at oncology and inflammatory metabolic disease indications.Nexentis said MITOLINE, its algorithm platform, enabled 3D structural modeling used to identify the initial hit molecule, which has now been advanced through medicinal-chemistry optimization.MitoCareX is moving toward lead selection ahead of pre-clinical trials.Nexentis said it controls about 98% of Save Foods, which focuses on post-harvest treatment technologies to reduce pathogen contamination in fruits and vegetables.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6w0Bvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4093","SG9999014021.USD","BK4112","BK4585","NXTS","BK4588","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789914","title":"Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789914","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789914?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:07","pubTimestamp":1778670420,"startTime":"0","endTime":"0","summary":"MITOLINE-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May  13, 2026  (GLOBE NEWSWIRE) -- Nexent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293861/0/en/Nexentis-Technologies-Announces-Optimization-of-Hit-Molecule-at-MitoCareX-Bio-Representing-Key-Drug-Discovery-Milestone.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633452662","title":"Nexentis Technologies Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633452662?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:54","pubTimestamp":1778248478,"startTime":"0","endTime":"0","summary":"09:35 EDT Nexentis Technologies (NXTS) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-inc-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nexentis-technologies-inc-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}